Trial results

Semaglutide 2.4mg for Low Responders After Bariatric Surgery

NCT06287307 on ClinicalTrials.gov · last registry update 2024-03-01

Registered but never opened — and the completion date on file, February 2026, has already passed. Its estimated completion date, February 2026, has passed with no update to the record. Primary outcome, as filed: Weight change from start study at 3 months post operative until 15 months later. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

NOT_YET_RECRUITING

Phase

P4

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Zuyderland Medisch Centrum

Sponsor type

Other

Enrollment

152

Started

2024-05

Primary completion

2026-02 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Weight change from start study at 3 months post operative until 15 months later

Conditions studied

Obesity · Obesity, Morbid · Weight Gain

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.